Literatur
-
1
Bennett J M, Catovsky D, Daniel M T. et al .
Proposals for
the classification of the acute leukaemias. French- American-British
(FAB) co-operative group.
Br J Haematol.
1976;
33
451-458
-
2 Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health
Organization Classification of Tumours. Pathology and Genetics of
Tumours of Haematopoietic and Lymphoid Tissues. Lyon,
IARC Press 2001
-
3
Haferlach T, Schoch C, Schnittger S, Kern W, Loffler H, Hiddemann W.
Distinct genetic patterns
can be identified in acute monoblastic and acute monocytic leukaemia
(FAB AML M5a and M5b): a study on 124 patients.
Br J Haematol.
2002;
118
426-431
-
4
Haferlach T, Schoch C.
WHO classification of
acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS).
Dtsch
Med Wochenschr.
2002;
127
447-450
-
5
Schoch C, Haferlach T, Haase D. et
al .
Patients with de novo acute myeloid leukaemia and
complex karyotype aberrations show a poor prognosis despite intensive
treatment: a study of 90 patients.
Br J Haematol.
2001;
112
118-126
-
6
Grimwade D, Walker H, Oliver F. et al .
The importance of diagnostic cytogenetics
on outcome in AML: analysis of 1,612 patients entered into the MRC
AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia
Working Parties.
Blood.
1998;
92
2322-2333
-
7
Schoch C, Kern W, Krawitz P. et
al .
Dependence of age-specific incidence of acute myeloid
leukemia on karyotype.
Blood.
2001;
98
3500
-
8
Lengfelder E, Reichert A, Schoch C. et al. German AML Cooperative Group .
Double induction
strategy including high dose cytarabine in combination with all-trans
retinoic acid: effects in patients with newly diagnosed acute promyelocytic
leukemia.
Leukemia.
2000;
14
1362-1370
-
9
Ostermann H, Derigs H G, Heussel G. et al .
Sepsis in neutropenia. Standard recommendations
of the Work Group of Infections in Hematology and Oncology of the
German Association for Hematology and Oncology.
Dtsch
Med Wochenschr.
1999;
124
S14-S17
(Suppl 1)
-
10
Buchner T, Hiddemann W, Wormann B. et al .
Double induction strategy for acute myeloid
leukemia: The effect of high-dose cytarabine with mitoxantrone instead
of standard-dose cytarabine with daunorubicin and 6-thioguanine:
A randomized trial by the German AML Cooperative Group.
Blood.
1999;
93
4116-4124
-
11
Kern W, Haferlach T, Schoch C. et al .
Early blast clearance by remission induction
therapy is a major independent prognostic factor for both achievement
of complete remission and long-term outcome in acute myeloid leukemia:
data from the German AML Cooperative Group 1992 Trial.
Blood.
(in press);
-
12
Hiddemann W, Kern W, Schoch C. et
al .
Management of acute myeloid leukemia in elderly
patients.
J Clin Oncol.
1999;
17
3569-3576
-
13
Mayer R J, Davis R B, Schiffer C A. et al. Cancer and Leukemia Group B .
Intensive
postremission chemotherapy in adults with acute myeloid leukemia.
N
Engl J Med.
1994;
331
896-903
-
14
Buchner T, Urbanitz D, Hiddemann W. et al .
Intensified induction and consolidation
with or without maintenance chemotherapy for acute myeloid leukemia
(AML): two multicenter studies of the German AML Cooperative Group.
J
Clin Oncol.
1985;
3
1583-1589
-
15
Cassileth P A, Harrington D P, Appelbaum F R. et al .
Chemotherapy compared
with autologous or allogeneic bone marrow transplantation in the management
of acute myeloid leukemia in first remission (see comments).
N
Engl J Med.
1998;
339
1649-1656
-
16
Kern W, Schoch C, Fonatsch C. et
al .
Therapie der akuten myeloischen Leukämie
bei Patienten im höheren Lebensalter.
Dtsch Med
Wochenschr.
1999;
124
1005-1014
-
17
Leith C P, Kopecky K J, Godwin J. et al. A Southwest Oncology Group study .
Acute
myeloid leukemia in the elderly: assessment of multidrug resistance
(MDR1) and cytogenetics distinguishes biologic subgroups with remarkably
distinct responses to standard chemotherapy.
Blood.
1997;
89
3323-3329
Dr. med. Wolfgang Kern
Klinikum der Universität München-Großhadern, Medizinische
Klinik III
81366 München
Phone: 089/70954986
Fax: 089/70954971
Email: wolfgang.kern@med3.med.uni-muenchen.de
